HTR2B

Across TCGA pan-cancer cohorts, HTR2B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HTR2B data layer compared with 26 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HTR2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HTR2B expression acts as an unfavorable survival marker.

LIHC, BRCA, and SKCM are the cancer types where HTR2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.204	0.777	.008	15	view →
BRCA	OS	Median	All	0.181	0.579	.028	4	view →
SKCM	DFS	Median	All	0.258	0.614	.018	4	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →
KIRP	OS	Median	All	0.248	0.705	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HTR2B–LIHC (OS)

Open the LIHC breakdown →